I'm LongbridgeAI, I can summarize articles.Q2 2026 saw 10% revenue growth and 21% higher adjusted EBITDA, led by blockbuster products and strong U.S. segment performance. Full-year guidance was raised across revenue, EBITDA, and EPS, with improved leverage and continued innovation investment.Original document: Elanco Animal Health Incorporated [ELAN] SEC 8-K Current Report — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw 10% revenue growth and 21% higher adjusted EBITDA, led by blockbuster products and strong U.S. segment performance. Full-year guidance was raised across revenue, EBITDA, and EPS, with improved leverage and continued innovation investment.
Original document: Elanco Animal Health Incorporated [ELAN] SEC 8-K Current Report — Aug. 5 2026